Forma Life Sciences, Inc. Launches as Independent U.S.-Based CDMO
Forma Life Sciences, Inc. has officially launched as an independent, operator-owned contract development and manufacturing organization focused exclusively on oral solid dosage formulation development, clinical manufacturing, and commercial drug product production within the United States. The company enters the market at a time when pharmaceutical manufacturers and biotechnology innovators are placing renewed emphasis on strengthening domestic manufacturing capacity and enhancing supply chain resilience to ensure reliable access to essential medicines.
Formation Through Strategic Acquisition
Forma Life Sciences was established following BioSelective Capital Investments’ acquisition of the U.S. drug product development and manufacturing operations of BioDuro, a global contract research and manufacturing organization. The transaction included two established Good Manufacturing Practice facilities located in Irvine, California, each with a long-standing regulatory history supporting both clinical and commercial oral solid dosage programs. By acquiring these operational assets, Forma inherits decades of pharmaceutical manufacturing expertise, established regulatory compliance systems, and a proven record of delivering high-quality products to partners worldwide.
Integrated U.S.-Based Oral Solid Dosage Platform
Forma operates two cGMP-compliant facilities in Irvine totaling more than 100,000 square feet and comprising 27 GMP manufacturing suites. These facilities collectively support oral solid dosage formulation development, clinical manufacturing for Phase I through Phase III programs, process scale-up and technical transfer, and full commercial drug product manufacturing. The combined manufacturing platform has the capacity to produce more than two billion tablet and capsule units annually, positioning Forma as a significant U.S.-based manufacturing resource for pharmaceutical and biotechnology companies seeking domestic production capabilities.
Comprehensive Development and Manufacturing Capabilities
The company delivers integrated formulation development and manufacturing services for tablets and capsules, supporting clients from early-stage clinical development through large-scale commercial production. Forma offers specialized expertise in spray-dried dispersion technologies for amorphous solid dispersion systems, enabling improved bioavailability for poorly soluble compounds. In addition, the organization operates commercial-scale fluid bed granulation and coating systems for modified-release and multiparticulate dosage forms, including matrix-based controlled-release and delayed-release technologies. These advanced capabilities allow pharmaceutical partners to address complex formulation challenges while maintaining scalability from clinical batches to commercial supply volumes.
Leadership with Proven Industry Experience
Forma’s leadership team includes executives who previously played key roles in building and operating the acquired business. The company is led by Cyrus K. Mirsaidi, Executive Chairman and Chief Executive Officer, who served as CEO of BioDuro from 2015 to 2021. He is joined by Armand Amin, President and Head of Business Operations, who previously held senior leadership roles within BioDuro. Their collective experience spans more than three decades of supporting the pharmaceutical supply chain, providing operational continuity while establishing a newly focused CDMO platform centered on disciplined execution and long-term strategic partnerships.
Commitment to Domestic Manufacturing and Supply Chain Resilience
According to Cyrus Mirsaidi, Forma was created to preserve the strong operational foundation built over decades while constructing a focused U.S.-based CDMO platform designed to meet evolving industry demands. The renewed emphasis on domestic pharmaceutical manufacturing has intensified as companies seek to reduce reliance on overseas production and mitigate supply disruptions. Armand Amin emphasized that Forma provides a durable and dependable U.S.-based development and manufacturing platform that pharmaceutical and biotechnology partners can rely on from clinical development through sustained commercial supply, reinforcing supply chain security and operational reliability.
Operational Launch and Headquarters
Forma Life Sciences began operating as an independent entity in January 2026 and is headquartered in Irvine, California. By centralizing leadership and manufacturing operations in a major U.S. biotechnology hub, the company is positioned to serve both established pharmaceutical organizations and emerging biotech innovators with flexible, scalable manufacturing solutions supported by experienced technical teams and regulatory expertise.
About Forma Life Sciences, Inc.
Forma Life Sciences is a U.S.-based contract development and manufacturing organization specializing in oral solid dosage formulation development, clinical manufacturing, and commercial drug product production. Operating two cGMP facilities in Irvine totaling more than 100,000 square feet and 27 GMP manufacturing suites, the company has capacity to produce more than two billion tablet and capsule units annually. Forma supports pharmaceutical and biotechnology partners from early clinical development through full commercial-scale manufacturing, offering advanced capabilities in spray-dried dispersion, amorphous solid dispersion systems, fluid bed granulation, and modified-release formulation technologies.
About BioSelective Capital Investments
BioSelective Capital Investments, together with Shayan Enterprises, LLC, a Utah-based risk-capital investment company, selectively invests in the biopharmaceutical sector through collaborations that combine equity investments with hands-on operational partnerships. With more than 10 active projects, the firm has developed a track record of delivering sustainable revenue growth and maximizing profit margins through disciplined sales expansion and cost management strategies. By deploying motivated and culturally diverse teams alongside capital resources, BioSelective focuses on well-defined and measurable operational goals designed to build accountability and energize sales organizations to achieve critical milestones and revenue targets within growth-oriented life sciences businesses.
Source link:https://www.businesswire.com/
